All In Biotech

Drug Trial Radar · NCT06897579

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

A Randomized Controlled, Open-label, Multicenter Clinical Trial Evaluating the Efficacy and Safety of Carboplatin/Cisplatin + Etoposide + Bemarituzumab Followed by Bemarituzumab Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Followed by Tislelizumab as First-line Treatment for Extensive-stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

40

Actual

Start

Apr 7, 2025

Primary completion

Apr 15, 2026

Study completion Apr 15, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, open-label, multicenter clinical study to evaluate the efficacy and safety of carboplatin/cisplatin + etoposide + benmelstobart sequential benmelstobart combined with anlotinib versus carboplatin/cisplatin + etoposide + Tislelizumab sequential Tislelizumab in the first-line treatment of extensive stage small cell lung cancer.

Conditions

  • Extensive Stage Small Cell Lung Cancer

Interventions

  • Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsuleDrug

    Carboplatin for injection inhibits DNA synthesis, thereby preventing cancer cell division and reproduction/Cisplatin for injection binds to DNA, interfering with DNA replication and transcription processes, Thus inhibiting tumor cell proliferation/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Bemosubebezumab injection is a humanized recombinant anti-Programmed cell death ligand 1 (PD-L1) monoclonal antibody/Anlotinib hydrochloride capsule is a tyrosine kinase inhibitor.

  • Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injectionDrug

    Carboplatin for injection inhibits DNA synthesis and thus prevents the division and reproduction of cancer cells/Cisplatin for injection binds to DNA and interferes with the DNA replication and transcription process, thereby inhibiting the proliferation of tumor cells/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Tislelizumab injection is a humanized recombinant anti-PD-1 monoclonal antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: From enrollment until the first onset of disease progression or death from any cause, evaluation is expected to take 2 years

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Maanshan People's Hospital

    Maanshan, Anhui, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Peking University People´s Hospital

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Fujian Medical University 2nd Affiliated Hospital

    Quanzhou, Fujian, China

  • The Second Hospitai. & Clinicae Medical School . Lanzhou University

    Lanzhou, Gansu, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Nanfang Hospital

    Guangzhou, Guangzhou, China

  • The fourth hospital of hebei medical university

    Shijiazhuang, Hebei, China

  • Tangshan People's Hospital

    Tangshan, Hebei, China

  • The First Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • The Second People's Hosital of Jiaozuo

    Jiaozuo, Henan, China

  • Henan Provincial People'S Hospital

    Zhengzhou, Henan, China

  • Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Jingzhou Central Hospital

    Jingzhou, Hubei, China

  • Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Baotou Cancer Hospital

    Baotou, Inner Mongolia, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Jinzhou Medical University

    Jinzhou, Liaoning, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shenyang Tenth People's Hospital

    Shenyang, Liaoning, China

  • The First Affiliated Hospital of Shandong First Medical University

    Jinnan, Shandong, China

  • Linyi City People's Hospital

    Linyi, Shandong, China

  • The Second Affiliated Hospital Of Xi'an Jiaotong University

    Xi'an, Shannxi, China

  • Shanxi Cancer hospital

    Taiyuan, Shanxi, China

  • Sichuan cancer hospital

    Chengdu, Sichuan, China

  • Dongyang Municipal People's Hospital

    Dongyang, Zhejiang, China

  • Ningbo Medical Center Lihuili Hospital

    Ningbo, Zhejiang, China

  • Ningbo No.2 Hospital

    Ningbo, Zhejiang, China

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.